CD274 and neoplasm: Immune checkpoint inhibition alone for PD-L1 high-expressing tumours and combined with cytotoxic chemotherapy for PD-L1 low-expressing tumours have become the standard of care for first-line treatment of advanced NSCLC; however, this treatment approach does not have a high overall effect.